非洲疫苗引入进展:疫苗十年期间的变化
该研究利用WHO-UNICEF联合报告表数据,概述了2017年WHO非洲区域国家的新疫苗和未充分利用疫苗的引入情况。结果显示,到2017年所有47个国家均已引入含乙肝疫苗和Hib疫苗,其他疫苗引入比例也显著提高,且Gavi支持是主要驱动力。
要点
- 到2017年,非洲区域所有47国均已引入乙肝疫苗和Hib疫苗。
- PCV、轮状病毒疫苗、MCV2和RCV的引入比例分别达83%、72%、55%和45%。
- Gavi支持国家更可能引入Hib,非Gavi支持国家更可能引入MCV2和RCV。
核心结论
- 非洲在引入新儿童疫苗方面取得了显著进展,主要由Gavi支持驱动。
- 随着许多国家即将退出Gavi支持,需要建立可预测、可靠和可持续的免疫筹资机制。
研究设计与样本
- 基于WHO-UNICEF联合报告表数据的描述性分析,覆盖WHO非洲区域47个国家。
- 比较了2000年、2010年和2017年疫苗引入比例,并分析了Gavi支持资格国(N=36)与非资格国(N=10)的差异。
主要发现
- 2017年所有47国均引入含乙肝疫苗(2000年11%,2010年98%)和Hib疫苗(2000年4%,2010年91%)。
- 2017年PCV引入比例83%(2010年7%),轮状病毒疫苗72%(2010年2%),MCV2 55%(2000年11%,2010年17%),RCV 45%(2000年4%,2010年7%)。
- 2000-2010年,Gavi资格国与非资格国在乙肝疫苗和PCV引入上无显著差异;Gavi资格国更可能引入Hib,非资格国更可能引入MCV2和RCV。
- 2010-2017年,两组间仅腮腺炎、灭活脊灰和季节性流感疫苗引入存在显著差异,非Gavi资格国更可能引入。
关键数值与推荐
- 到2017年,47国全部引入含乙肝疫苗和Hib疫苗。
- PCV引入比例83%,轮状病毒疫苗72%,MCV2 55%,RCV 45%。
临床怎么用
- 应关注即将退出Gavi支持国家的免疫规划可持续筹资。
- 需采取超越疫苗采购的承诺和行动,确保疫苗持续供应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines are excellent investments with far-reaching rewards beyond individual and population health, but their introduction into national programs has been historically slow in Africa. We provide an overview of the introduction of new and underutilized vaccines in countries of the WHO African Region by 2017, using data from the WHO-UNICEF Joint Reporting Form. By 2017, all 47 countries had introduced vaccines containing hepatitis B (compared to 11% in 2000 and 98% in 2010) and Haemophilus influenzae type b (Hib) (compared to 4% in 2000 and 91% in 2010). The proportion of countries that had introduced other vaccines by 2017 was 83% for pneumococcal conjugate vaccine (PCV) from 7% in 2010, 72% for rotavirus vaccine from 2% in 2010, 55% for the second dose of a measles-containing vaccine (MCV2) (compared to 11% in 2000 and 17% in 2010), and 45% for rubella-containing vaccines (RCV) (compared to 4% in 2000 and 7% in 2010). From 2000 to 2010, there was no significant difference between countries eligible (N = 36) and those not eligible (N = 10) for Gavi support in the introduction of hepatitis B and PCV. However, Gavi eligible countries were more likely to introduce Hib and non-Gavi eligible countries were more likely to introduce MCV2 and RCV. From 2010 to 2017, the only significant differences that remained between the two groups of countries were with mumps, inactivated polio and seasonal influenza vaccines; which non-Gavi eligible countries were more likely to have introduced. There has been significant progress in the introduction of new childhood vaccines in Africa, mostly driven by Gavi support. As many countries are expected to transition out of Gavi support soon, there is need for countries in the region to identify predictable, reliable and sustainable immunization funding mechanisms. This requires commitments and actions that go beyond the purchase of vaccines.
引用
- Sambala EZ, Wiyeh AB, Ngcobo N, et al. New vaccine introductions in Africa before and during the decade of vaccines - Are we making progress? Vaccine. 2019. PMID: 31076160. doi:10.1016/j.vaccine.2019.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。